Literature DB >> 25724820

Hepatitis B vaccination among adolescents 13-17 years, United States, 2006-2012.

Peng-jun Lu1, David Yankey2, Jenny Jeyarajah2, Alissa O'Halloran2, Laurie Elam-Evans2, Stacie M Greby2, James A Singleton2, Trudy V Murphy3.   

Abstract

BACKGROUND: Hepatitis B (HepB) vaccination is the most effective measure to prevent HBV infection. Routine HepB vaccination was recommended for infants in 1991 and catch-up vaccination has been recommended for adolescents since in 1995. The purpose of this study is to assess HepB vaccination among adolescents 13-17 years.
METHODS: The 2006-2012 NIS-Teen were analyzed. Vaccination trends and coverage by birth cohort among adolescents were evaluated. Multivariable logistic regression and predictive marginal models are used to identify factors independently associated with HepB vaccination.
RESULTS: HepB vaccination coverage increased from 81.3% in 2006 to 92.8% in 2012. Coverage varied by birth cohort and 79-83% received vaccination before 2 years of age for those who were born during 1995 and 1999. Among those who had not received vaccination by 11 years of age, for the 1993-1995 birth cohorts, 9-15% were vaccinated during ages 11-12 years, and 27-37% had been vaccinated through age 16 years. Coverage among adolescents 13-17 years in 2012 ranged by state from 84.4% in West Virginia to 98.7% in Florida (median 93.3%). Characteristics independently associated with a higher likelihood of HepB vaccination included living more than 5 times above poverty level, living in Northeastern or Southern region of the United States, and having a mixed facility as their vaccination provider. Those with a hospital listed as their vaccination provider and those who did not have a well-child visit at age 11-12 years were independently associated with a lower likelihood of HepB vaccination.
CONCLUSIONS: Efforts focused on groups with lower coverage may reduce disparities in coverage and prevent hepatitis B infection. Parents and providers should routinely review adolescent immunizations. Routine reminder/recall, expanded access in health care settings, and standing order programs should be incorporated into routine clinical care of adolescents. Published by Elsevier Ltd.

Entities:  

Keywords:  Adolescent vaccination; Coverage; Hepatitis B vaccine; The National Immunization Survey-Teen (NIS-Teen); Vaccination

Mesh:

Substances:

Year:  2015        PMID: 25724820      PMCID: PMC5808397          DOI: 10.1016/j.vaccine.2015.02.021

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  33 in total

1.  FDA approval for infants of a Haemophilus influenzae type b conjugate and hepatitis B (recombinant) combined vaccine.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1997-02-07       Impact factor: 17.586

2.  Seasonal influenza vaccination coverage among adult populations in the United States, 2005-2011.

Authors:  Peng-Jun Lu; James A Singleton; Gary L Euler; Walter W Williams; Carolyn B Bridges
Journal:  Am J Epidemiol       Date:  2013-09-05       Impact factor: 4.897

Review 3.  Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis.

Authors:  Chuanfang Lee; Yan Gong; Jesper Brok; Elizabeth H Boxall; Christian Gluud
Journal:  BMJ       Date:  2006-01-27

4.  Primary care physician perspectives on reimbursement for childhood immunizations.

Authors:  Gary L Freed; Anne E Cowan; Sarah J Clark
Journal:  Pediatrics       Date:  2008-12       Impact factor: 7.124

5.  Gaps in vaccine financing for underinsured children in the United States.

Authors:  Grace M Lee; Jeanne M Santoli; Claire Hannan; Mark L Messonnier; James E Sabin; Donna Rusinak; Charlene Gay; Susan M Lett; Tracy A Lieu
Journal:  JAMA       Date:  2007-08-08       Impact factor: 56.272

6.  Meningococcal conjugate vaccine uptake, measured by Michigan's immunization registry.

Authors:  Kyle S Enger; Shannon Stokley
Journal:  J Adolesc Health       Date:  2007-03-09       Impact factor: 5.012

7.  Evaluating accountability in the Vaccines for Children program: protecting a federal investment.

Authors:  Pamela L Y H Ching
Journal:  Public Health Rep       Date:  2007 Nov-Dec       Impact factor: 2.792

8.  National, state, and local area vaccination coverage among children aged 19-35 months - United States, 2012.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-09-13       Impact factor: 17.586

9.  National and state vaccination coverage among adolescents aged 13-17 years--United States, 2012.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-08-30       Impact factor: 17.586

10.  Noninfluenza vaccination coverage among adults - United States, 2011.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-02-01       Impact factor: 17.586

View more
  4 in total

1.  Varicella Vaccination Among US Adolescents: Coverage and Missed Opportunities, 2007-2014.

Authors:  Jessica Leung; Sarah Reagan-Steiner; Adriana Lopez; Jenny Jeyarajah; Mona Marin
Journal:  J Public Health Manag Pract       Date:  2019 May/Jun

2.  Estimating Annual Births to Hepatitis B Surface Antigen-Positive Women in the United States by Using Data on Maternal Country of Birth.

Authors:  Alaya Koneru; Sarah Schillie; Henry Roberts; Barry Sirotkin; Nancy Fenlon; Trudy V Murphy; Noele P Nelson
Journal:  Public Health Rep       Date:  2019-04-03       Impact factor: 2.792

3.  Characteristics of Pregnant Women With Hepatitis B Virus Infection in 5 US Public Health Jurisdictions, 2008-2012.

Authors:  Tanja Y Walker; Emily A Smith; Nancy Fenlon; Julie E Lazaroff; Cristina Dusek; Patrick Fineis; Susan A Crowley; Ruthie Benson; Steven L Veselsky; Trudy V Murphy
Journal:  Public Health Rep       Date:  2016-08-22       Impact factor: 2.792

4.  Progress in vaccination towards hepatitis B control and elimination in the Region of the Americas.

Authors:  Alba Maria Ropero Álvarez; Silvia Pérez-Vilar; Carmelita Pacis-Tirso; Marcela Contreras; Nathalie El Omeiri; Cuauhtémoc Ruiz-Matus; Martha Velandia-González
Journal:  BMC Public Health       Date:  2017-04-17       Impact factor: 3.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.